- CertainT® Integration with TruTrace
StrainSecure™ Platform to Power Flora Growth’s Global Distribution
Strategy -
Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing and nucleic acid-based technologies, today announced
that it has entered into a Master Services Agreement (the “MSA”)
with Flora Growth (NASDAQ: FLGC) (Flora) to deploy the Company’s
CertainT® platform as part of Flora’s global cannabis product
validation and authentication platform for consumers, distributors,
and government regulators. Concurrently, the Company received a
Statement of Work (SOW) under the MSA from Flora to implement its
CertainT platform and supply related equipment and services for
three locations (1 in Florida; 2 in the Republic of Colombia),
where the Company’s molecular tags will be applied to quantities of
Flora’s cannabis flower and derivatives, as well as select products
in their portfolio. Financial terms of the SOW were not
disclosed.
The MSA is the result of the Company’s strategic alliance,
referral, and technology integration agreement with TruTrace
Technologies, Inc. (CSE: TTT; OTCQB: TTTSF) (TruTrace) under which
TruTrace’s blockchain-based StrainSecure™ platform was integrated
with CertainT to deliver a complete, end-to-end supply chain
security solution to cannabis companies. Flora will employ the
integrated CertainT-StrainSecure solution to support its product
validation and authentication platform to be utilized to deliver on
Flora’s previously announced commercial agreements to export
cannabis products internationally to open markets like
Australia.
Flora, a manufacturer and wholesaler of cannabis and cannabis
derivative products and operator of one of the largest outdoor
cannabis cultivation facilities, is differentiated by its use of
natural ingredients and value-chain sustainability. Flora’s
cannabis derivative products are used in premium cosmetics, hemp
textiles, and food and beverage applications.
“Business imperatives centered on branding and supply chain
mastery will be the defining characteristics of cannabis companies
positioning to compete globally. To that end, CertainT’s value
proposition delivers brand and product differentiation, IP
protection, and supply chain security from inception to consumption
that, we believe, will further catalyze interest and adoption of
our platform,” stated Dr. James A. Hayward, president and CEO of
Applied DNA. “CertainT offers customers like Flora unmatched levels
of transparency, traceability, and trust across their supply chains
that are further improved through our integration with TruTrace. We
are very pleased to undertake our first international commercial
cannabis venture alongside Flora and, given its growing and diverse
portfolio of cannabis and cannabis derivative products, we believe
we are in the early stages of a mutually beneficial commercial
relationship with Flora.”
Robert Galarza, CEO of TruTrace, stated, “The first fruits of
our partnership with Applied DNA have been realized and at a time
when the cannabis industry’s globalization has accelerated the need
for solutions to verify supply chains in defense of a brand’s
intellectual property and brand equity. Companies like Flora, who
recognize and address this need, will hold a competitive advantage
in the market and offer compelling value to end-customers. The
integration of our platform with CertainT is designed specifically
to meet that need.”
About the CertainT® Platform
The CertainT platform has three technology pillars (Tag, Test,
Track), which allows raw materials and products to be tagged with a
unique molecular identifier. This identifier can then be tested for
its presence as it travels throughout a global supply chain. All
the data points associated to tagging and testing are tracked by
uploading to a secure cloud database. The CertainT platform can be
used across industries such as textiles, cannabis, military,
leather, fertilizer, pharmaceuticals, personal care.
About Flora Growth Corp.
Flora is a cannabis company that leverages natural,
cost-effective cultivation practices to supply cannabis derivatives
to its diverse business divisions of cosmetics, hemp textiles, and
food and beverage. As the operator of one of the largest outdoor
cultivation facilities, Flora strives to market a higher-quality
premium product at below market prices. By prioritizing natural
ingredients and value-chain sustainability across its portfolio,
Flora creates premium products that help consumers restore and
thrive. Visit http://www.floragrowth.ca/ or follow @floragrowthcorp
on social for more information.
About TruTrace Technologies
TruTrace Technologies is the developer of fully-integrated
software, secured on a blockchain infrastructure, that gives
clients’ the ability to store, manage, share and immediately access
quality assurance and testing details, COAs, as well as motion and
movement intelligence on inventory. The platform was specifically
designed to power the traceability of testing standards within the
legal cannabis, nutraceutical, food and pharmaceutical space with a
focus on the authentication of source materials or ingredients used
in formulation. For more information, please visit
https://www.trutrace.co/.
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction (“PCR”)-based manufacturing
platform that allows for the large-scale production of specific DNA
sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a
pooled COVID-19 testing program that is grounded in the Company’s
EUA-authorized Linea™ COVID-19 Assay Kit. safeCircle is designed to
look for infection within defined populations or communities
utilizing pooled testing methodologies that increase testing
efficiencies. The Company has also developed and plans to seek
EUA-authorization for its LineaTM SARS-CoV-2 Mutation Panel, an
assay-based panel for the detection of certain SARS-CoV-2 genetic
mutations.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies, and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance,
including Applied DNA’s ability to successfully enter into
commercial contracts for the implementation of its CertainT®
platform, shifting enforcement priorities of US federal laws and
other international laws relating to cannabis and cannabis
derivative products, and various other factors detailed from time
to time in Applied DNA’s SEC reports and filings, including our
Annual Report on Form 10-K filed on December 17, 2020, and
Quarterly Reports on Form 10-Q filed on February 11, 2021, May 13,
2021, and August 12 2021, and other reports we file with the SEC,
which are available at www.sec.gov. Applied DNA undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005731/en/
For Applied DNA: Investor contact: Sanjay M.
Hurry, 917-733-5573, sanjay.hurry@adnas.com Program contact:
John Sherman, 631-240-8838, john.sherman@adnas.com Web:
www.adnas.com Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024